A ALNY
Alnylam Pharmaceuticals Inc
BIOTECHNOLOGY · HEALTHCARE
Alnylam Pharmaceuticals, Inc. is a leading biopharmaceutical company based in Cambridge, Massachusetts, specializing in RNA interference (RNAi) therapeutics to address genetic diseases. The company has successfully launched its first commercial product and boasts a diverse pipeline of innovative RNA...
$325.07
-2.36% ($7.85)
Volume
1.30M
52W High
$495.55
52W Low
$205.87
Market Cap
$42.58B
Next Earnings Report
Last Reported
Feb 12, 2026 Met
Actual: $1.25
vs. Consensus: $1.24
Price Chart
EPS History: Consensus vs Actual
Last 12 quartersPrice Movement Around Earnings
Q4 2025
Feb 12, 2026
1-Day:
+1.92%
5-Day:
+7.82%
Q3 2025
Oct 30, 2025
1-Day:
+1.44%
5-Day:
-5.80%
Q2 2025
Jul 31, 2025
1-Day:
+2.44%
5-Day:
+6.80%
Q1 2025
May 1, 2025
1-Day:
+1.67%
5-Day:
+5.75%
Revenue & Financial Performance
| Quarter | Revenue | YoY Growth | Gross Margin | Op Margin | Net Income |
|---|---|---|---|---|---|
| Q4'25 | $1.10B | +85.0% | 75.6% | 12.0% | $186.4M |
| Q3'25 | $1.25B | +149.4% | 84.2% | 29.5% | $251.1M |
| Q2'25 | $773.7M | +17.3% | 81.5% | -2.1% | -$66.3M |
| Q1'25 | $594.2M | +20.2% | 88.0% | 3.0% | -$57.5M |
| Q4'24 | $593.2M | +34.9% | 82.7% | -17.7% | -$83.8M |
| Q3'24 | $500.9M | -33.3% | 82.9% | -15.4% | -$111.6M |
| Q2'24 | $659.8M | +107.0% | 89.6% | 7.4% | -$16.9M |
| Q1'24 | $494.3M | +54.8% | 86.7% | -8.8% | -$65.9M |
Company Information
Symbol
ALNY
Company
Alnylam Pharmaceuticals Inc
Market Cap
$42.58B
Sector
HEALTHCARE
HEALTHCARE Stocks
Other healthcare companies with earnings data
More in BIOTECHNOLOGY
Compare ALNY with competitors
Side-by-side earnings comparison